Top 3 Criteria for Selecting Investigator Initiated Trials to Fund: Strategy Alignment, Scientific Merit and Strong Investigator Credentials

Natalie DeMasi, clinical development and medical affairs researcher
By Natalie DeMasi,
Research Analyst

There are many different names for investigator sponsored trials (ISTs), such as investigator initiated trials (IITs), investigator sponsored studies (ISS), investigator initiated research (IIR) and a number of other variants of those titles that you can think of.  IITs – or whatever sobriquet you prefer – vary in budget, patient population, phase and research goals even more than they vary in name.  But one thing does not change about investigator sponsored trials: the need to carefully select which trials are worth funding and which ones are not. Continue reading


Upholding Physician Fair-Market Value: It All Starts with a Formal Rate Card

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Developing competitive rates, to recruit key industry experts has never been the easiest of tasks for life sciences companies.  Add in the additional complexity associated with Sunshine Act reporting requirements and the recruitment process become even more difficult.  In this heightened regulatory environment, recruiting top-tier physicians and other thought leader types means that companies must balance their desire to remain competitive with adhering to rates that do not fall too far astray of physician fair-market values. Continue reading


Pharma Key Opinion Leader Development Requires a Personal Touch

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

At a recent conference I attended focused on pharma advisory boards, one of the presentations focused on KOL relationships and best practices for maintaining effective contact with thought leaders.  One of the key takeaways for me in terms of pharma key opinion leader development was the need to ensure that there is a personal touch to communications.  This corroborated a lot of what we’ve seen here in our research at Cutting Edge Information.  Continue reading


Small Pharma KOL Management Leans Heavily on Existing Networks Within Companies

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

When it comes to managing and nurturing thought leader relationships and specifically the process of identifying key opinion leaders, companies have several options. Many choose to outsource the identification process and contact KOLs once they’ve been identified by the third-party vendor. For larger and mid-sized companies that are looking to expand into new therapeutic areas or geographic regions, vendors provide an extremely valuable and effective service. Continue reading


Pharma Digital Marketing: Making Your Company an Invaluable Information Resource

Eric Bolesh, commercialization and alliance management expert
By Eric Bolesh,
Senior Director

Over the years, pharmaceutical companies’ digital marketing activities have enabled them to adopt a different approach to reaching patients, caregivers and physicians alike. Beyond direct-to-consumer television ads and email sends, many organizations have branched out to incorporate new channels within their existing marketing strategies. To be certain, companies have developed a number of innovative branded and unbranded pharma digital marketing solutions using a multitude of platforms. For example, companies have launched Facebook pages, Twitter accounts and YouTube channels geared toward specific audiences as a means to generate campaign awareness and promote consumer education. However, with the growth of the technological age and digital capabilities, correcting misinformation can be just as much of a challenge as disseminating company and product information. Continue reading


Selecting the Right Key Opinion Leader is Imperative in an Era of Increased Transparency

Eric Bolesh, commercialization and alliance management expert
By Eric Bolesh,
Senior Director

GlaxoSmithKline recently announced that it will create an internal team of doctors tasked with educating peers about its products. In December 2013, GSK decided to stop hiring external speakers. The company hopes that “hiring doctors and medical experts to speak as in-house representatives of Glaxo will provide more transparency,” according to Deirdre Connelly, GSK president, North America pharmaceuticals. The decision to form an internal education team underscores the importance of engaging physicians in discussions regarding product efficacy. When making prescribing decisions, physicians look to well-respected peers to affirm their choices as they seek to treat patients using the best possible options. Continue reading


New Year’s Resolutions for Pharma Teams

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

As 2013 comes to a close, the Pharmaceutical and Life Science industries are gearing up for new challenges and new opportunities in 2014. Cutting Edge Information is pleased to present a snapshot of our 2014 Forecasting Guide. Every team will have unique New Year’s resolutions to meet challenges and embrace opportunities. Cutting Edge Information’s research team offers options for deepening key opinion leader engagement, boosting health economics investment, listening more closely to the Voice of the Patient, refining drug development plans earlier and forecasting clinical costs more accurately, among others. Continue reading